Current Environment:

Warning

Recall Alert

There is a voluntary recall. Learn more

Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (PD) and pharmacokinetic (PK) effect of VX-561.

Conditions

Cystic Fibrosis

Recruitment Status

COMPLETED

Eligibility Criteria

Key Inclusion Criteria:

* Must have 1 of the following 9 CFTR mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D
* On ivacaftor therapy
* FEV1 value ≥40% and ≤100% of predicted mean for age, sex, and height

Key Exclusion Criteria:

* History of clinically significant cirrhosis with or without portal hypertension
* History of solid organ or hematological transplantation
* Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply

Intervention

Intervention Type

Intervention Name

DRUG

VX-561

DRUG

IVA

DRUG

Placebo

DRUG

Placebo

Phase

PHASE2

Gender

ALL

Min Age

18 Years

Max Age

N/A

Download Date

2022-01-25

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis NCT03911713